Latest Hotspot

PTC Therapeutics Reports FDA Acceptance and Priority Review of Upstaza™ BLA

17 May 2024
3 min read

PTC Therapeutics, Inc. revealed today that the FDA has officially received the Biologics License Application for Upstaza™ (eladocagene exuparvovec), a gene therapy aimed at treating AADC deficiency. The submission has been given Priority Review status, with a projected regulatory decision date set for November 13, 2024.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, Teams

描述已自动生成

Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics, expressed enthusiasm about advancing towards providing an approved treatment for patients in the U.S. who suffer from AADC deficiency. "The cumulative data thus far supports the significant transformative potential of Upstaza, a pioneering gene therapy that is administered directly to the brain," he remarked.

Designed as a one-time gene replacement therapy, Upstaza is meant for patients 18 months and older diagnosed clinically, molecularly, and genetically with severe aromatic L–amino acid decarboxylase deficiency. This treatment employs a recombinant adeno-associated virus serotype 2 (AAV2) vector containing the human DDC gene to correct the genetic defect. By delivering the functional DDC gene directly into the putamen, Upstaza aims to boost AADC enzyme levels and restore dopamine synthesis.

Clinical trials and compassionate use programs have consistently shown Upstaza’s efficacy and safety profile since the first patient was treated in 2010. These trials have highlighted major neurological improvements, with initial insomnia, irritability, and dyskinesia being the most frequent side effects.

Upstaza is delivered via a stereotactic surgical method, a minimally invasive procedure frequently used to address various pediatric and adult neurological disorders. This procedure, specific to specialized neurosurgery centers, is conducted by trained neurosurgeons.

Eladocagene exuparvovec, which targets the DDC gene, is indicated for treating Aromatic Amino Acid Decarboxylase Deficiency within the therapeutic domains of endocrinology and metabolic diseases. The drug received its initial approval in the European Union, Iceland, Liechtenstein, and Norway in July 2022, following an expedited review by health authorities.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of May 16, 2024, there are 19 investigational drugs for the DDC target, including 21 indications,49 R&D institutions involved, with related clinical trials reaching 306, and as many as 7748 patents.

The approval of Eladocagene exuparvovec represents a significant achievement in the pharmaceutical industry, offering a promising new treatment option for patients with Aromatic Amino Acid Decarboxylase Deficiency. As the drug continues to be evaluated and potentially approved in other regions, it has the potential to make a meaningful impact on the lives of individuals affected by this rare genetic disorders.

图形用户界面, 文本, 应用程序

描述已自动生成

Verismo Therapeutics gets FDA's IND approval for SynKIR™-310 in treating relapsed/refractory B-cell NHL
Latest Hotspot
3 min read
Verismo Therapeutics gets FDA's IND approval for SynKIR™-310 in treating relapsed/refractory B-cell NHL
17 May 2024
Verismo Therapeutics announced that the FDA has approved a Phase 1 clinical trial for SynKIR™-310 to evaluate its effectiveness for NHL.
Read →
AriBio Gains IND Approval from China's NMPA for Phase 3 Alzheimer's Trial, POLARIS-AD
Latest Hotspot
3 min read
AriBio Gains IND Approval from China's NMPA for Phase 3 Alzheimer's Trial, POLARIS-AD
17 May 2024
This approval allows for the commencement of the Phase 3 Polaris-AD trial for AR1001 in early Alzheimer's Disease in China starting May 11th, 2024.
Read →
Fulcrum Therapeutics and Sanofi Partner on Losmapimod for FSHD Treatment
Latest Hotspot
3 min read
Fulcrum Therapeutics and Sanofi Partner on Losmapimod for FSHD Treatment
17 May 2024
Fulcrum Therapeutics and Sanofi sign an agreement for Losmapimod's development and marketing in treating Facioscapulohumeral Muscular Dystrophy.
Read →
Azura Ophthalmics Presents AZR-MD-001 Data as Potential First Keratolytic for Ocular Surface Diseases
Pharma Pioneer
3 min read
Azura Ophthalmics Presents AZR-MD-001 Data as Potential First Keratolytic for Ocular Surface Diseases
17 May 2024
The data reveal that the experimental AZR-MD-001 has shown lasting effects in enhancing the ocular symptoms of Meibomian Gland Dysfunction (MGD) after a six-month treatment period.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.